erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
“it may be just out of an abundance of caution and privacy. certainly, staying a little longer may imply that this is a little bit more of a complex situation.”